Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and CEO Christopher Anzalone, Ph.D., was featured in a Medical Research, Diagnostic Substances & Life Science Tools Report published by The Wall Street Transcript.

Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview

Pasadena, CA | Posted on June 16th, 2011

Topics covered by Dr. Anzalone include Arrowhead's operational and clinical progress with its RNAi, obesity and regenerative medicine programs, the Company's paradigm shifting technologies under development, strategic growth initiatives and key catalysts for which investors and industry experts should watch for in the near-term.

Dr. Anzalone's interview can be accessed on the Company's website at: www.arrowheadresearch.com.

Published on June 14, 2011, this edition of interviews by The Wall Street Transcript offers a timely review of the sector containing expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue may be obtained by calling (212) 952-7433 or via The Wall Street Transcript Online.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that we will be able to maintain our listing on any NASDAQ market, that our financial initiatives will succeed or that we will be able to continue to operate as a going concern. Arrowhead Research Corporation's Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company.

To be added to the Company's email list to receive news directly, please send an email to

For more information, please click here

Contacts:
Investor Relations Contact:
Brandi Floberg
The Piacente Group, Inc.
212-481-2050

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Flexible Metamaterial Absorbers July 29th, 2014

ACS Biomaterials Science & Engineering™: Brand-new journal names editor July 29th, 2014

Harris & Harris Group Invests in Unique NYC Biotech Accelerator July 29th, 2014

Tough foam from tiny sheets: Rice University lab uses atom-thick materials to make ultralight foam July 29th, 2014

Nanomedicine

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

New imaging agent provides better picture of the gut July 25th, 2014

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals

ACS Biomaterials Science & Engineering™: Brand-new journal names editor July 29th, 2014

Tough foam from tiny sheets: Rice University lab uses atom-thick materials to make ultralight foam July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

A new way to make microstructured surfaces: Method can produce strong, lightweight materials with specific surface properties July 29th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE